Donald M Jensen
Affiliation: University of Chicago
- IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late?Donald M Jensen
Center for Liver Diseases, University of Chicago, Chicago, IL 60637, USA
Liver Int 32:74-8. 2012..In summary, although it was a major milestone in the treatment of patients with PEG-IFN/RBV, IL28B polymorphism testing entered the clinical arena almost 10 years too late...
- Future directions in therapy for chronic hepatitis CDonald M Jensen
Center for Liver Diseases, University of Chicago Hospitals, Chicago, IL, USA
Antivir Ther 13:31-6. 2008..Nevertheless, because of its critical role at all stages of therapy, pegylated interferon is likely to remain the cornerstone of HCV therapy...
- Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trialDonald M Jensen
Center for Liver Diseases, University of Chicago Hospitals, Chicago, Illinois 60637, USA
Ann Intern Med 150:528-40. 2009..Many patients with chronic hepatitis C have not responded to therapy with pegylated interferon plus ribavirin...
- Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapyDonald M Jensen
Center for Liver Diseasees, University of Chicago Hospitals, 60637, USA
Hepatology 43:954-60. 2006..In conclusion, patients infected with HCV genotype 1 and treated with peginterferon alpha-2a/ribavirin sustained a RVR 24% of the time. This portends an 89% probability of a SVR after 24 weeks of treatment...
- Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatmentPatrick Marcellin
Hopital Beaujon, boulevard du General Leclerc, Clichy, France Instituto Di Clinica Medica Policlinico, Palermo Department of Clinical Medicine, University of Bologna, Bologna, BO, Italy Internal Medicine Department, Hepatology Division, Gaffrée e Guinle University Hospital, College of Medicine and Surgery, University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil Department of Internal Medicine, Saint Louis University School of Medicine, St Louis Kansas City Gastroenterology and Hepatology, LLC, Kansas City, Mo Division of Gastroenterology, University of Pennsylvania, Philadelphia, PA Hospital La Paz de Madrid, Madrid, Spain Interdisziplinäres Facharztzentrum Sachsenhausen, MVZ Sachsenhausen, Frankfurt IST GmbH, Mannheim, Germany Roche Products Ltd, Welwyn, UK F Hoffmann La Roche Ltd, Basel, Switzerland Center for Liver Diseases, University of Chicago Hospitals, Chicago, IL
J Clin Gastroenterol 47:786-93. 2013....
- Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirinDonald M Jensen
Rush University Medical Center, Chicago, Illinois 60612, USA
Eur J Gastroenterol Hepatol 17:899-904. 2005....
- Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirinNancy Reau
Center for Liver Diseases, University of Chicago Hospitals, Chicago, Illinois 60637, USA
Am J Gastroenterol 103:1981-8. 2008..The objective of this analysis was to elucidate baseline and on-treatment factors predictive of a considerable hemoglobin drop at week 4...
- A pilot study of the combination of cyclosporin A and interferon alfacon-1 for the treatment of hepatitis C in previous nonresponder patientsScott J Cotler
Rush Presbyterian St Luke s Medical Center, Chicago, Illinois, USA
J Clin Gastroenterol 36:352-5. 2003..To evaluate the safety and efficacy of the combination of interferon and cyclosporine for the treatment of hepatitis C in previous nonresponder patients...
- Use of immune function test in monitoring immunosuppression in liver transplant recipientsHelen S Te
Center for Liver Diseases, University of Chicago Medical Center, Chicago, IL 60637, USA
Clin Transplant 26:826-32. 2012..IFT may be a useful tool in monitoring and lowering of immunosuppression in long-term OLT recipients...
- Induction of IL-1Ra in resistant and responsive hepatitis C patients following treatment with IFN-con1Scott J Cotler
Section of Hepatology and Department of Preventive Medicine, RUSH Presybterian St Luke s Medical Center, Chicago, IL 60612, USA
J Interferon Cytokine Res 22:549-54. 2002....
- Epidemiology of hepatitis B and C viruses: a global overviewHelen S Te
Liver Transplantation, Center for Liver Diseases, Department of Medicine, University of Chicago Medical Center, 5841 South Maryland Avenue, MC 7120, Chicago, IL 60637, USA
Clin Liver Dis 14:1-21, vii. 2010..Public education regarding the risks of exposure to infected paraphernalia as well as household items such as razors is necessary in the continuing effort to curb this disease...
- Retreatment of chronic hepatitis C in previous non-responders and relapsersRohit Satoskar
Center for Liver Diseases, University of Chicago, Section of Gastroenterology, 5841 S Maryland, MC7120, Chicago, IL 60637, USA
Expert Opin Pharmacother 8:2491-503. 2007..The review ends with the authors' opinion regarding present management of non-responders and relapsers and future emerging therapies...
- Vanishing bile duct syndromeNancy S Reau
Center for Liver Diseases, Section of Gastroenterology, Department of Medicine, University of Chicago Medical Center, 5841 S Maryland, MC7120, Chicago, IL 60637, USA
Clin Liver Dis 12:203-17, x. 2008..This article reviews the multiple causes, postulated pathophysiology, clinical features, and treatment options for this syndrome...
- The importance of rapid viral suppression in the era of directly acting antiviral therapy for hepatitis C virusErin T Jenkins
Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago Medical Center, MC 4076 Room M 421, 5841 South Maryland, Chicago, IL 60637, USA
Infect Dis Clin North Am 26:879-91. 2012....
- Future therapies for chronic hepatitis CNoura M Dabbouseh
Department of Medicine, Section of Gastroenterology, Hepatology and Nutrition, University of Chicago Medical Center, 5841 South Maryland Avenue, MC7120, Chicago, IL 60637, USA
Nat Rev Gastroenterol Hepatol 10:268-76. 2013..This Review chronicles the latest developments in hepatitis C therapy and the potential effect these new treatments could have on delivery of care to patients infected with HCV...
- Neutralizing antibodies in hepatitis C virus infection: a review of immunological and clinical characteristicsMitchell Kaplan
Department of Internal Medicine, Rush Presbyterian St Luke s Medical Center, Rush University, Chicago, IL 60612, USA
Gastroenterology 125:597-604. 2003
- Current state of combined heart-liver transplantation in the United StatesHelen S Te
Center for Liver Diseases, Department of Medicine, University of Chicago Medical Center, Chicago, Illinois 60637, USA
J Heart Lung Transplant 27:753-9. 2008..Combined heart-liver transplantation (CHLT) has been increasingly performed in the USA, but published data on overall patient and graft outcomes have been limited...
- Influence of ethnicity on histological differences in non-alcoholic fatty liver diseaseSmruti R Mohanty
Department of Medicine, Center for Liver Diseases, University of Chicago, 5841 S Maryland Avenue, MC 7120, Chicago, IL 60637 1463, USA
J Hepatol 50:797-804. 2009..Previous studies examining ethnic differences in non-alcoholic fatty liver disease (NAFLD) are limited by small sample sizes and the lack of liver biopsy as a diagnostic modality...
- Adult living donor liver transplantation: perspectives from 100 liver transplant surgeonsScott J Cotler
Rush Presbyterian St Luke s Medical Center, Chicago, IL, USA
Liver Transpl 9:637-44. 2003..In conclusion, the findings of this survey indicate that transplant surgeons are working to balance their moral imperative to provide life-saving therapy for transplantation candidates with the risks posed to living donors...
- The downstream financial effect of hepatologyStanley Martin Cohen
Department of Internal Medicine, Rush University Medical Center, Chicago, IL 60612, USA
Hepatology 41:968-75. 2005..This study validates the importance of a hospital's support for a Hepatology section, especially in a center performing orthotopic liver transplantation...
- Prevalence and significance of autoantibodies in patients with non-alcoholic steatohepatitisScott J Cotler
University of Illinois at Chicago, Chicago, Illinois, USA
J Clin Gastroenterol 38:801-4. 2004..The aim of this study is to evaluate the prevalence and the clinical and histologic correlates of autoantibodies in patients with nonalcoholic steatohepatitis (NASH)...
- Ribavirin in the treatment of chronic hepatitis CPaul Martin
University of Miami, Miami, Florida, USA
J Gastroenterol Hepatol 23:844-55. 2008..We review its mechanism of action, its importance in treating chronic hepatitis C (CHC) patients, the AE associated with its use, and techniques used to lessen these AE...
- Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis CStefan Zeuzem
Klinik fur Innere Medizin II, Universitatskliniken des Saarlandes, 66421 Homburg Saar, Germany
J Hepatol 39:106-11. 2003..Sensitive molecular tests may permit earlier determination of sustained virologic response following the completion of therapy in end-of-treatment responders...
- Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirinMichael W Fried
University of North Carolina, Chapel Hill, NC 27514, USA
Hepatology 48:1033-43. 2008..The arm with the higher doses of both drugs was less well-tolerated than the other regimens...
- Characteristics of hepatitis C in renal transplant candidatesScott J Cotler
Department of Medicine, Rush Presbyterian St Luke s Medical Center, Chicago, Illinois 60612, U S A
J Clin Gastroenterol 35:191-5. 2002..To characterize hepatitis C in renal transplant candidates and to compare hepatitis C-related liver disease between patients with end-stage renal disease (ESRD) and well-matched control subjects without renal disease...